COLORADO SPRINGS, Colo., Oct. 4 /PRNewswire-FirstCall/ -- Spectranetics Corporation (NASDAQ:SPNC) announced today that it has received clearance from the Food and Drug Administration (FDA) to market its TURBO elite(TM) product line for the treatment of blockages within leg arteries.
This new product line is designed for improved pushability, trackability and ablation capability as a result of an improved outer jacket and inner guidewire lumen and additional laser fibers in most sizes. Further, it incorporates all of the features of the TURBO product line, including 80 hertz laser repetition rates, "continuous on" lasing and a hydrophilic coating. TURBO elite products will be launched in a limited market release in the fourth quarter of 2006, with full commercialization expected in early 2007.
"The TURBO elite product line demonstrates our commitment to continuing innovation within the large and growing peripheral arterial disease market. It includes a number of physician-sponsored product improvements and represents our third generation of peripheral laser catheters," said John G. Schulte, Spectranetics' president and chief executive officer.
Spectranetics is a medical device company that develops, manufactures and markets single-use medical devices used in minimally invasive surgical procedures within the cardiovascular system in conjunction with its proprietary excimer laser system. Excimer laser technology delivers relatively cool ultraviolet energy to ablate or remove arterial blockages including plaque, calcium and thrombus. We believe our CVX-300® excimer laser is the only system approved in the United States, Europe, Japan, and Canada for use in multiple, minimally invasive cardiovascular procedures. These procedures include atherectomy, which is a procedure to remove arterial blockages in the peripheral or coronary vasculature, and the removal of infected, defective or abandoned cardiac lead wires from patients with pacemakers or implantable cardiac defibrillators, or ICDs, which are electronic devices that regulate the heartbeat.
Source: Spectranetics Corporation
CONTACT: Guy Childs, Chief Financial Officer of Spectranetics Corporation, +1-719-633-8333; or Bruce Voss or Don Markley, both of Lippert/Heilshorn & Associates, Inc., +1-310-691-7100, for Spectranetics Corporation
Web site: http://www.spectranetics.com/